Abiopharma

🔍 PROEHL GERALD T (Director)

Company: Dermata Therapeutics, Inc. (DRMA)

Report Date: 2025-08-16

Detailed Transactions and Holdings:

• Acquired 170,068 shares of Common Stock (Direct)
  Date: 2026-08-16 | Code: A | equity_swap_involved: 0 | shares_owned_after: 292,631.00 | transaction_form_type: 4 | Footnotes: F1, F2, F5
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-08-16 | Code: H | shares_owned_after: 24.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-08-16 | Code: H | nature_of_ownership: By Allison Taylor Proehl 2020 Irrevocable Trust | shares_owned_after: 7.00 | Footnotes: F5
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-08-16 | Code: H | nature_of_ownership: By Meghan Proehl Wilder 2020 Irrevocable Trust | shares_owned_after: 3.00 | Footnotes: F5
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-08-16 | Code: H | nature_of_ownership: By Proehl Investment Ventures LLC | shares_owned_after: 79,950.00 | Footnotes: F5
• Acquired 1,360,544 shares of Series E Warrant (Right to Buy) at $1.47 per share (Derivative)
  Date: 2026-08-16 | Code: A | equity_swap_involved: 0 | shares_owned_after: 1,360,544.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3, F3, F5
• Acquired 1,360,544 shares of Series F Warrant (Right to Buy) at $1.47 per share (Derivative)
  Date: 2026-08-16 | Code: A | equity_swap_involved: 0 | shares_owned_after: 1,360,544.00 | transaction_form_type: 4 | Footnotes: F1, F2, F4, F4, F5
• Acquired 170,068 shares of Series E Warrant (Right to Buy) at $1.47 per share (Derivative)
  Date: 2026-08-16 | Code: A | equity_swap_involved: 0 | shares_owned_after: 170,068.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3, F3, F5
• Acquired 170,068 shares of Series F Warrant (Right to Buy) at $1.47 per share (Derivative)
  Date: 2026-08-16 | Code: A | equity_swap_involved: 0 | shares_owned_after: 170,068.00 | transaction_form_type: 4 | Footnotes: F1, F2, F4, F4, F5
• Acquired 1,360,544 shares of Pre-Funded Warrant (Right to Buy) at $0.001 per share (Derivative)
  Date: 2026-08-16 | Code: A | Exercise: 2026-08-16 | equity_swap_involved: 0 | shares_owned_after: 1,360,544.00 | transaction_form_type: 4 | Footnotes: F1, F2, F6, F3, F5

Footnotes:

• F1: The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the "Private Placement"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Each share of common stock (or pre-funded warrant in lieu thereof) was purchased together with (i) a series E warrant to purchase one share of common stock and (ii) a series F warrant to purchase one share of common stock.
• F2: The purchase price per share of common stock and accompanying warrants was $1.47 and the purchase price of each pre-funded warrant and accompanying warrants was $1.469.
• F3: This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common stock issuable upon exercise of the warrants. The warrant will expire five years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions.
• F4: This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants. The warrant will expire two years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions.
• F5: The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
• F6: The pre-funded warrant has no expiration date.